Icecure Medical logo
ICCMIcecure Medical
Trade ICCM now
Icecure Medical primary media

About Icecure Medical

Icecure Medical (TASE:ICCM), (NASDAQ:ICCM) specializes in developing and marketing minimally invasive cryoablation therapies for treating tumors. This innovative approach allows for the destruction of tumors by freezing without the need for traditional surgical removal. Icecure Medical's flagship project, ProSense, is a state-of-the-art system designed to provide a nonsurgical alternative for patients with tumors in various organs, including the breast, kidney, bone, and lungs. The company's objective is to transform cancer treatment by offering safer, cost-effective, and less invasive solutions compared to conventional surgeries, expanding the possibilities for cancer care worldwide. Icecure Medical aims to continue advancing its technology and increase its market presence, demonstrating a commitment to improving patient outcomes and quality of life.

What is ICCM known for?

Snapshot

Public US
Ownership
2006
Year founded
74
Employees
Caesarea, Israel
Head office
1 of 5
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

All Locations
State of Israel

Products and/or services of Icecure Medical

  • ProSense® Cryoablation System: This is IceCure's main offering. It's a minimally invasive system that utilizes liquid nitrogen to freeze and destroy tumors. ProSense® is marketed as an alternative to surgical tumor removal for various types of cancers, including breast, kidney, bone, and lung.
  • Training and Support: They might offer training programs for medical professionals on how to safely and effectively use the ProSense® system.
  • Customer Service: IceCure Medical likely provides customer service support to hospitals and clinics using their system, addressing technical issues or inquiries.
  • Clinical Trial Support: The company might be involved in sponsoring or conducting clinical trials to evaluate the effectiveness of the ProSense® system for different applications.
  • Data Collection and Analysis: IceCure Medical might collect and analyze data on the use of the ProSense® system to improve its effectiveness and develop new applications.

Icecure Medical executive team

  • Mr. Eyal ShamirCEO & Director
  • Mr. Ronen Tsimerman CPAChief Financial Officer
  • Mr. Shay LevavChief Operating Officer
  • Ms. Tlalit Bussi Tel-TzureVice President of Business Development & Global Marketing
  • Mr. Shad GoodVice President of Sales for North America
  • Ms. Merav Nir DotanVice President of Human Resources
  • Ms. Galit MalikVice President of Operations & Service

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.